

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

APOTEX INC., APOTEX CORP., APOTEX PHARMACEUTICALS
HOLDINGS INC., AND APOTEX HOLDINGS, INC.,

Petitioners,

v.

OSI PHARMACEUTICALS, INC.,

Patent Owners.

Case IPR2016-01284
Patent No. 6,900,221 B1

DECLARATION OF AMY K. WIGMORE IN SUPPORT OF
MOTION FOR ADMISSION *PRO HAC VICE*

I, Amy K. Wigmore, declare as follows:

1. I was admitted to the Massachusetts Bar in January of 1996 and the District of Columbia Bar in December of 1996. I have been practicing law for 20 years. For more than 10 years, my practice has focused primarily on patent litigation.
2. Over the course of my career, I have been counsel in dozens of patent litigations.
3. I am a member in good standing in the Bars of Massachusetts and the District of Columbia and am admitted to practice before the U.S. District Courts for the District of Columbia, District of Colorado, and District of Massachusetts. I am also admitted to practice before the U.S. Court of Appeals for the Federal Circuit, the D.C. Circuit, and the Sixth Circuit, as well as the Supreme Court of the United States.
4. My Massachusetts Bar membership number is 629275. My District of Columbia Bar membership number is 453164.
5. I have never been suspended or disbarred from practice before any court or administrative body.
6. I have never had a court or administrative body deny my application for admission to practice.

7. I have never had any sanctions or contempt citations imposed by any court or administrative body.

8. I have read and will comply with the Patent Office Trial Practice Guide and the Board's Rules for Practice for Trials, as set forth in 37 C.F.R. Part 42.

9. I agree to be subject to the United States Patent and Trademark Office Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 *et seq.* and disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

10. In the last three (3) years, I have appeared *Pro Hac Vice* before the Patent Trial and Appeal Board six times, in the following cases: *Coherus Biosciences Inc. v. AbbVie Biotechnology Ltd.*, Case IPR2016-00172; *Coherus Biosciences Inc. v. AbbVie Biotechnology Ltd.*, Case IPR2016-00188; *Coherus Biosciences Inc. v. AbbVie Biotechnology Ltd.*, Case IPR2016-00189; *Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. v. AbbVie Biotechnology Ltd.*, Case IPR2016-00408; *Boehringer Ingelheim International GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. v. AbbVie Biotechnology Ltd.*, Case IPR2016-004089; and *OSI Pharmaceuticals LLC and Genentech, Inc. v. Arch Development Corp. and Dana-Farber Cancer Institute, Inc.*, Case IPR2016-01034 (*pro hac vice* motion pending).

11. In addition to this matter, I have represented OSI Pharmaceuticals, LLC in multiple patent and patent-related cases, including: *OSI Pharmaceuticals, LLC v.*


Apotex Inc., Civ. No. DED-1-15-cv-00772 (D. Del.); *OSI Pharmaceuticals, LLC v. Breckenridge Pharmaceutical, Inc.*, Civ. No. DED-1-15-cv-01063 (D. Del.); and *Arch Development Corporation v. Genentech, Inc.*, Civ. No. ILND-1-15-cv-06597 (N.D. Ill.).

12. I am intimately familiar with the subject matter of U.S. Patent No. 6,900,221. I am also intimately familiar with tyrosine kinase inhibitor technology as a result of my participation as counsel in cases related to such subject matter, including the cases listed in the previous paragraph. In addition, I have represented a number of life sciences and pharmaceutical companies—including AbbVie, Inc.; Bristol-Myers Squibb Company; GlaxoSmithKline plc; Pfizer Inc.; Wyeth; and others—in many patent litigation matters before federal district courts and appellate courts. The technology involved in these disputes includes methods of treating cancer involving pharmaceutical compounds.

13. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like are punishable by fine, imprisonment, or both under Section 1001 of Title 18 of the United States Code.

Dated: January 30, 2017

Respectfully submitted,

_____

Amy K. Wigmore
WILMER CUTLER PICKERING
HALE AND DORR LLP
1875 Pennsylvania Avenue NW
Washington, DC 20006
(202) 663-6096